<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01407575</url>
  </required_header>
  <id_info>
    <org_study_id>BUP-TRD</org_study_id>
    <nct_id>NCT01407575</nct_id>
  </id_info>
  <brief_title>Buprenorphine for Treatment Resistant Depression</brief_title>
  <acronym>BUP-TRD</acronym>
  <official_title>Buprenorphine For Treatment Resistant Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Alliance for Research on Schizophrenia and Depression</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and efficacy of buprenorphine with placebo
      for adults with treatment resistant depression (TRD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rates of treatment resistant depression (TRD) in randomized controlled trials range from
      50-80% using SSRIs and SNRIs. Innovative treatments are sorely needed. Modulation of the
      opiate system may be a novel treatment approach for TRD. Buprenorphine (BUP) is a partial
      agonist at mu-receptors, and also displays affinity for kappa and delta receptors. BUP has a
      favorable safety profile with low risk of respiratory depression, and the pharmacokinetics
      are not affected by advanced age or renal dysfunction. This combination of mu-agonism and
      kappa-antagonism produces less dysphoria than methadone, and animal studies suggest that
      kappa-antagonism may exert antidepressant effects. In this small proof of concept RCT (n=20),
      the investigators hypothesize that there will be differences between the group receiving
      buprenorphine and the group receiving placebo for the following: 1) depression, anxiety, and
      sleep, and 2)activation of the limbic system and brain structures rich in opiate receptors
      and critical to reward circuits. In addition, the investigators hypothesize that there will
      not be differences for measures of safety (vital signs, measures of memory and reaction time,
      and falls) between the two groups. This pilot project will provide compelling preliminary
      data to support a R01 application to test the efficacy of buprenorphine for these
      therapeutically challenging patients.

      Specific Aims:

        1. Describe the relative safety of BUP in adults with TRD. The investigators hypothesize
           that there will be no differences in vital signs, measures of memory and reaction time,
           or falls between the two groups.

        2. Describe the clinical effect of BUP in adults with TRD. The investigators hypothesize
           that depression, anxiety, sleep, and health-related quality of life, will improve to a
           greater extent among those receiving BUP.

        3. Characterize the change in the phMRI responses to buprenorphine compared to placebo. The
           investigators will compare activation of the limbic system (rACC, insula, and amygdala)
           and brain structures rich in opiate receptors (periaqueductal grey) and critical to
           reward circuits (nucleus accumbens) before and immediately after administration of BUP
           or placebo.

      The investigators are recruiting 20 community-dwelling adults, age 21 and older, who have
      tried at least two FDA-approved antidepressant medications at therapeutic doses each for at
      least 6 weeks during this episode of depression, and are still depressed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale</measure>
    <time_frame>6 weeks</time_frame>
    <description>measure of depression severity Theoretical Range 0-60 lower values represent better outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>6 weeks</time_frame>
    <description>Measure of systolic and diastolic blood pressure. 140/90 or lower is considered normal and indicates a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>UKU Side Effect Rating Scale</measure>
    <time_frame>6 weeks</time_frame>
    <description>measure of side effects 46 items with scores of 0,1,2,3 possible. Theoretical range 0-138 Lower scores indicate fewer side effects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>Heart Rate (Beats per minute) 60-100 beats per minute is considered normal lower heart rate represent healthier outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight</measure>
    <time_frame>6 weeks</time_frame>
    <description>Participant weight</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brief Symptom Inventory -- Anxiety Subscale</measure>
    <time_frame>6 weeks</time_frame>
    <description>measure of anxiety Lower numbers indicate better outcome Theoretical Range 0-2.4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Affect Scale</measure>
    <time_frame>6 weeks</time_frame>
    <description>Positive Affect Score: Scores can range from 10 - 50, with higher scores representing higher levels of positive affect.
Negative Affect Score: Scores can range from 10 - 50, with lower scores representing lower levels of negative affect.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Depression</condition>
  <condition>Depressive Disorder</condition>
  <condition>Depressive Disorder, Major</condition>
  <arm_group>
    <arm_group_label>Buprenorphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.2 to 1.6mg of buprenorphine sublingual over the course of 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo- sublingual- over the course of 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>low-dose buprenorphine (range 0.2 mg/day -- 1.6 mg/day)</description>
    <arm_group_label>Buprenorphine</arm_group_label>
    <other_name>suboxone</other_name>
    <other_name>buprenex</other_name>
    <other_name>temgesic</other_name>
    <other_name>subutex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matched placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 21 and older

          -  Major depressive disorder

          -  Non-responder to at least 2 FDA-approved antidepressants prescribed at a therapeutic
             dose, each for at least 6 weeks, or is a depression non-responder from an ongoing
             study of late-life depression at our research clinic.

          -  For women of child-bearing age, must have negative pregnancy test and agree not to get
             pregnant while participating.

        Exclusion Criteria:

          -  Concomitant use of strong or moderate CYP3A4 inhibitor.

          -  Refusal to stop all opioids.

          -  Refusal to discontinue all alcohol.

          -  Refusal to discontinue benzodiazepines other than the equivalent of lorazepam 2 mg/day
             prescribed at a stable dose for at least the past 2 weeks.

          -  Hepatic impairment (AST/ALT &gt; 1.5 times upper normal).

          -  Lung disease requiring supplemental oxygen (CPAP for sleep apnea is acceptable).

          -  Estimated creatinine clearance &lt;30 mL/min.

          -  Inability to provide informed consent.

          -  Depressive symptoms not severe enough (i.e., MADRS &lt; 10) at the baseline assessment.

          -  Dementia, as defined by MMSE &lt; 24 and clinical evidence of dementia

          -  Lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective
             disorder, schizophreniform disorder, delusional disorder, or current psychotic
             symptoms.

          -  Abuse of or dependence on alcohol or other substances within the past 3 months.

          -  Meets criteria for history of abuse or dependence upon opioids.

          -  High risk for suicide.

          -  Contraindication to buprenorphine.

          -  Inability to communicate in English.

          -  Non-correctable clinically significant sensory impairment.

          -  Unstable medical illness.

          -  Subjects taking psychotropic medications that cannot be safely tapered and
             discontinued prior to study initiation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jordan F Karp, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Western Psychiatric Institute and Clinic, University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2011</study_first_submitted>
  <study_first_submitted_qc>August 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2011</study_first_posted>
  <results_first_submitted>January 5, 2016</results_first_submitted>
  <results_first_submitted_qc>February 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 17, 2016</results_first_posted>
  <last_update_submitted>February 9, 2018</last_update_submitted>
  <last_update_submitted_qc>February 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Jordan F. Karp</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Buprenorphine</keyword>
  <keyword>Receptors, opioid</keyword>
  <keyword>Receptors, opioid, kappa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Buprenorphine</title>
          <description>Buprenorphine: low-dose buprenorphine (range 0.2 mg/day -- 1.6 mg/day)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: matched placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Buprenorphine</title>
          <description>Buprenorphine: low-dose buprenorphine (range 0.2 mg/day -- 1.6 mg/day)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: matched placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.92" spread="15.88"/>
                    <measurement group_id="B2" value="64.59" spread="5.01"/>
                    <measurement group_id="B3" value="59.66" spread="12.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Montgomery Asberg Depression Rating Scale</title>
        <description>measure of depression severity Theoretical Range 0-60 lower values represent better outcome</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Buprenorphine: low-dose buprenorphine (range 0.2 mg/day -- 1.6 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Montgomery Asberg Depression Rating Scale</title>
          <description>measure of depression severity Theoretical Range 0-60 lower values represent better outcome</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8" spread="10.96"/>
                    <measurement group_id="O2" value="32.6" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Pressure</title>
        <description>Measure of systolic and diastolic blood pressure. 140/90 or lower is considered normal and indicates a better outcome.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Buprenorphine: low-dose buprenorphine (range 0.2 mg/day -- 1.6 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure</title>
          <description>Measure of systolic and diastolic blood pressure. 140/90 or lower is considered normal and indicates a better outcome.</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.4" spread="22.71"/>
                    <measurement group_id="O2" value="117.2" spread="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" spread="14.92"/>
                    <measurement group_id="O2" value="71" spread="15.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>UKU Side Effect Rating Scale</title>
        <description>measure of side effects 46 items with scores of 0,1,2,3 possible. Theoretical range 0-138 Lower scores indicate fewer side effects</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Buprenorphine: low-dose buprenorphine (range 0.2 mg/day -- 1.6 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>UKU Side Effect Rating Scale</title>
          <description>measure of side effects 46 items with scores of 0,1,2,3 possible. Theoretical range 0-138 Lower scores indicate fewer side effects</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2" spread="13.74"/>
                    <measurement group_id="O2" value="20.2" spread="5.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brief Symptom Inventory -- Anxiety Subscale</title>
        <description>measure of anxiety Lower numbers indicate better outcome Theoretical Range 0-2.4</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Buprenorphine: low-dose buprenorphine (range 0.2 mg/day -- 1.6 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Symptom Inventory -- Anxiety Subscale</title>
          <description>measure of anxiety Lower numbers indicate better outcome Theoretical Range 0-2.4</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="1.1"/>
                    <measurement group_id="O2" value="0.97" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive and Negative Affect Scale</title>
        <description>Positive Affect Score: Scores can range from 10 – 50, with higher scores representing higher levels of positive affect.
Negative Affect Score: Scores can range from 10 – 50, with lower scores representing lower levels of negative affect.</description>
        <time_frame>6 weeks</time_frame>
        <population>reduced sample size verified. This was secondary to administrative error.</population>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Buprenorphine: low-dose buprenorphine (range 0.2 mg/day -- 1.6 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Positive and Negative Affect Scale</title>
          <description>Positive Affect Score: Scores can range from 10 – 50, with higher scores representing higher levels of positive affect.
Negative Affect Score: Scores can range from 10 – 50, with lower scores representing lower levels of negative affect.</description>
          <population>reduced sample size verified. This was secondary to administrative error.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PANAS positive affect subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.75" spread="0.96"/>
                    <measurement group_id="O2" value="16.25" spread="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PANAS negative affect subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" spread="11.4"/>
                    <measurement group_id="O2" value="20.5" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Heart Rate</title>
        <description>Heart Rate (Beats per minute) 60-100 beats per minute is considered normal lower heart rate represent healthier outcome</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>0.2 to 1.6mg of buprenorphine sublingual over the course of 8 weeks
Buprenorphine: low-dose buprenorphine (range 0.2 mg/day -- 1.6 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matching placebo- sublingual- over the course of 8 weeks
Placebo: matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate</title>
          <description>Heart Rate (Beats per minute) 60-100 beats per minute is considered normal lower heart rate represent healthier outcome</description>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.25" spread="12.84"/>
                    <measurement group_id="O2" value="72.6" spread="19.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Weight</title>
        <description>Participant weight</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine</title>
            <description>Buprenorphine: low-dose buprenorphine (range 0.2 mg/day -- 1.6 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: matched placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Weight</title>
          <description>Participant weight</description>
          <units>lbs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191.7" spread="30.02"/>
                    <measurement group_id="O2" value="203.7" spread="12.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Buprenorphine</title>
          <description>Buprenorphine: low-dose buprenorphine (range 0.2 mg/day -- 1.6 mg/day)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: matched placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jordan F. Karp, MD</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-246-6048</phone>
      <email>karpjf@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

